Triciribine (API-2) Clinical Trials

Size	Price	Qty
5mg	USD 147
50mg	USD 570

Clinical Trials

Multiple clinical trials have evaluated triciribine in Phase 1 and Phase 1/2 studies across hematologic malignancies, such as acute leukemia and mucosa-associated lymphoid tissue lymphoma, and solid tumors, including breast adenocarcinoma and ovarian cancer. Sponsored by Prescient Therapeutics, VioQuest Pharmaceuticals, and National Taiwan University Hospital, these investigations characterized triciribine's safety, pharmacokinetics, and combination efficacy in advanced or refractory cancers. Recruitment statuses vary, spanning completed trials in hematologic and solid malignancies to terminated protocols in recurrent breast carcinoma and platinum-resistant ovarian cancer.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02930109	COMPLETED	Acute Leukemia	Prescient Therapeutics, Ltd.	2016-12-09	PHASE1; PHASE2
NCT01697293	TERMINATED	Breast Adenocarcinoma; Estrogen Receptor Positive; HER2/Neu Negative; Recurrent Breast Carcinoma; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer	Prescient Therapeutics, Ltd.	2012-01	PHASE1; PHASE2
NCT01690468	TERMINATED	Ovarian Cancer	Prescient Therapeutics, Ltd.	2014-09	PHASE1; PHASE2
NCT02987127	Unknown status	Mucosa-Associated Lymphoid Tissue Lymphoma	National Taiwan University Hospital	2016-02	--
NCT00642031	COMPLETED	Hematologic Malignancies; Leukemia	Prescient Therapeutics, Ltd.	2006-08	PHASE1
NCT00363454	COMPLETED	Cancer	Prescient Therapeutics, Ltd.	2006-04	PHASE1
NCT00642031	Completed	Hematologic Malignancies\|Leukemia	Prescient Therapeutics Ltd.\|VioQuest Pharmaceuticals	2006-08	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-04-05)

Check the Triciribine (API-2) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Triciribine selectively inhibits the phosphorylation and activation of Akt1, Akt2, and Akt3 without directly blocking upstream PI3K or PDK1, thereby disrupting downstream survival signaling and triggering apoptosis in Akt-dependent cells. This targeted suppression of Akt activation leads to cell growth arrest and tumor growth inhibition, providing therapeutic rationale for its clinical evaluation in Akt-driven malignancies such as acute leukemia, breast adenocarcinoma, and ovarian cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).